PARP Inhibitors in Oncology

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. This report covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.

Scope

GlobalData’s PARP Inhibitors in Oncology combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia.

Components of the report include:

• Overview of PARP Inhibitors in Oncology – Background, mechanism of action, and clinical development of PARP inhibitors.

• Epidemiology Analysis – Which current and future disease spaces are relevant to PARP inhibitors.

• Marketed PARP Inhibitors – How the currently approved PARP inhibitors compare.

• Pipeline Assessment in the 8MM – What are the pipeline PARP inhibitor products in development in oncology.

• Key Players – What companies are developing PARP inhibitors in oncology.

• Research and Development Strategies – How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.

• Pricing, Reimbursement, and Regulatory Strategies – What current and future challenges face PARP inhibitors from a payer’s perspective.

Reasons to Buy

Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.

Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

AbbVie
AstraZeneca
BeiGene
Clovis Oncology
Jiangsu Hengrui Medicine Co.
Merck
Nerviano Medical Sciences
Oncology Venture
Pfizer
Sanofi
SyntheX
Tesaro

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1 Table of Concents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL Insight on PARP Inhibitor Competitive Landscape

3. Overview – PARP Inhibitors

3.1 The Role of PARP in DNA Repair

3.2 Mechanism of PARP Inhibitors in Cancer

3.3 History of PARP Inhibitor Clinical Development

3.4 PARP Inhibitors in Ovarian Cancer

3.5 PARP Inhibitors in Breast Cancer

3.6 PARP Inhibitors in Prostate Cancer

3.7 PARP Inhibitors in Pancreatic Cancer

3.8 PARP Inhibitors in Other Cancers

3.9 PARP Inhibitor Resistance and Long-Term Effects

4. Epidemiology Analysis

4.1 Epidemiology Analysis – Ovarian Cancer

4.2 Epidemiology Analysis – Breast Cancer

4.3 Epidemiology Analysis – Prostate Cancer

4.4 Epidemiology Analysis – Pancreatic Cancer

4.5 Epidemiology Analysis – Gastric Cancer

5. Marketed PARP Inhibitors

5.1 Timeline of PARP Inhibitors Clinical Development in the 8MM

5.2 Currently Marketed PARP Inhibitors in Oncology

5.3 KOL Input on Marketed PARP Inhibitors

6. Pipeline Assessment in the 8MM

6.1 Assessment of Ongoing Trials of Marketed PARP Inhibitors

6.2 Talazoparib (Pfizer)

6.3 Veliparib (AbbVie)

6.4 Pamiparib (BeiGene)

6.5 2X-121 (Oncology Venture)

6.6 Fluzoparib (Jiangsu Hengrui Medicine Co.)

6.7 PARP Trapping

6.8 KOL Input on Pipeline PARP Inhibitors

7. Key Players

7.1 Companies Developing PARP Inhibitors in Oncology

7.2 Analysis of the Company Portfolio Gap in PARP Inhibitors

7.3 KOL Input on Key Players

8. Clinical Trials Mapping and Design

8.1 Ongoing Clinical Trials of PARP Inhibitors Pipeline

8.2 KOL Input on Challenges in PARP Inhibitor Clinical Trial Design

9. Combination Strategies with PARP Inhibitors

9.1 Overview of Clinical Trials of PARP Inhibitors as Combination Therapy

9.2 Combination Strategy of PARP Inhibitors with Immuno-oncology

9.3 Combination Strategy of PARP Inhibitors with Angiogenesis Inhibitors

9.4 Combination Strategy of PARP Inhibitors with Chemotherapy

9.5 Combination Strategy of PARP Inhibitors with Other Drugs

10. Pricing, Reimbursement, and Regulatory Strategy

10.1 Current Strategies for Oncology Products

10.2 Differentiating Between Lynparza, Rubraca, and Zejula

10.3 Future PARP Inhibitors

10.4 PARP Inhibitor Challenges from US/UK Payers’ Perspective

11. Market Outlook and Future Use

11.1 Market Outlook

11.2 Anticipated Key Events in PARP Inhibitors

11.3 Future Uses of PARP Inhibitors in Oncology

12. Appendix

12.1 Sources

12.2 Methodology

12.3 Primary Research

12.4 About the Authors

12.5 About GlobalData

Frequently asked questions

PARP Inhibitors in Oncology thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PARP Inhibitors in Oncology was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PARP Inhibitors in Oncology in real time.

  • Access a live PARP Inhibitors in Oncology dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.